Key Takeaways
- Margin guidance reset, not a miss: FY26 EBITDA margin guided to 23.5%–24.5%, down from FY25’s ~25.5%+ exit, driven by the impending loss of generic Revlimid exclusivity and a shifting product mix.
- U.S. business at an inflection point: Quarterly revenue guided to ~$220 mn for Q1 FY26 as lenalidomide compression begins; management expects new peptide, respiratory and injectable launches to rebuild the base, though the pace and overlap remain uncertain.
- India franchise proves resilience: Branded prescription, trade generics and consumer health all contributed to growth despite a weak acute season, pushing the chronic mix to 61.5% and demonstrating a derisked domestic portfolio.
- The pipeline is deep but gated: Four more respiratory ANDAs, 10 additional peptide/complex filings, and launches like inhaled insulin and Symbicort are on the 12–36 month horizon; near-term U.S. performance hinges on FDA review timelines and site-transfer approvals.
- What to watch next quarter: The actual slope of the lenalidomide decline, the launch cadence of nilotinib and nano paclitaxel in the U.S., and any further clarity on the Advair amendment timeline.
U.S. Revenue Trajectory & Pipeline
- Lenalidomide cliff is now: Management expects compression over the next 2–3 quarters as the product loses exclusivity toward the end of FY26; the quarterly U.S. run rate would have crossed $250 mn had lena stayed at current levels, but Q1 FY26 is guided to ~$220 mn.
- Offset strategy relies on new launches: Nilotinib is “imminent,” nano paclitaxel was recently approved, and three peptide assets are expected to launch in FY26, with one likely a large asset and two smaller; the full impact of many products will only show in second-half numbers.
- Respiratory pipeline advancing: Six assets already filed including generic Symbicort and Qvar; four more respiratory filings planned in the next 12–18 months; Symbicort launch expected in FY27.
- Advair gated by site transfer: The product will be commercialized from a U.S. facility; an amendment has already been filed with the FDA, but management declined to specify the filing date; launch is “definitely” FY26, either early or late depending on how the FDA prioritizes domestic site filings.
- Lanreotide supply normalizing: Q4 volumes were significantly higher than Q3, and the product is “quite significantly back into the channel”; production is returning to roughly the same levels as when Cipla held its previous market share, though filling the pipeline will take time.
Vohra: “Well, if lenalidomide stayed at where it was now, yes, we would have got there and crossed it. But you also have to see the next 2 or 3 quarters is when we will see a compression in lena. And that will be offset by these new products that are coming up.”
Margin Outlook & Mix Shift
- FY26 EBITDA guided lower at 23.5%–24.5%: The primary driver is the loss of high-margin generic Revlimid exclusivity, which will compress overall profitability as the year progresses; a changing product mix toward newly launched assets also contributes.
- FY25 exit exceeded guidance: EBITDA margin came in roughly 150 bps above the guided range, aided by favorable mix, calibrated price actions across branded and generic portfolios, and easing cost escalations.
- R&D ceiling unchanged: Management reiterated R&D spend will not exceed 6–6.5% of revenue on a full-year basis, though individual quarters may fluctuate; the business model does not support a higher structural rate.
- Capex rising for capacity and derisking: FY26 capex guided to ~5% of revenue, directed at expanding respiratory capacity (MDI, DPI, rescue inhalers) and building manufacturing capability outside India; a China respiratory facility has been capitalized and begun supply, and two U.S. facilities are being readied for MDI and DPI production.
India Business & Chronic Mix
- One India delivered despite acute headwinds: Growth came from branded prescription, trade generics and consumer health, with the 7% YoY expansion reflecting a mix of volume, pricing and new introductions rather than volume alone.
- Chronic mix reached 61.5%: Per IQVIA MAT March 2025, the portfolio continues to shift toward chronic therapies, improving revenue visibility and reducing dependence on seasonal acute categories.
- Trade generics trajectory sustained: Vigorous execution, distribution expansion, 19 new introductions during the year and technology adoption kept the business on an upward path, though Q4 FY25 was a normalized quarter versus a strong Q4 FY24, so YoY growth reflects normal comparatives.
- Consumer health delivered strong double-digit growth: Anchor brands Nicotex, Omnigel and Cipladine maintained number-one market positions; the wellness portfolio is a stated focus area for FY26 with new launches ramping up.
- Inhaled insulin positioned as a niche: Approved last quarter and expected to launch in 3–4 months; management sees it as an asset for patients with injectable phobia, targeting low single-digit share of the overall insulin market, not a replacement for injectable insulin.
Vohra: “The idea of inhaled insulin is never to replace the way insulin is served in the market in India. So we don't -- by its very nature, the asset is a niche asset for people who cannot take injectable drugs or people who are hesitant to take...”
International Markets & Regional Levers
- South Africa growth built on three levers: The Actor OTC acquisition, opportunistic tender participation, and new launches with higher share than competitors are driving outperformance; private market secondary growth of 6.7% outpaced the market at 4.9%.
- EMEU enters a growth phase: After four years of stability, the region delivered 15% USD growth led by deeper penetration in core markets across both DTM and B2B categories; margin stability is being sustained alongside the top-line expansion.
- North Africa also recorded robust growth: The broader One Africa segment enhanced its competitive edge, with secondary growth exceeding market growth.
- China respiratory plant now operational: The facility has been capitalized and is supplying respiratory medication for the China market; it can also supply other markets including the U.S. if required, though future filings will go from U.S. and India sites.
Regulatory, Tariffs & External Environment
- Five facilities classified VAI: U.S. FDA audited Patalganga, Kurkumbh, Goa, Virgonagar and Medispray during the year; all received Voluntary Action Indicated status, keeping the manufacturing base in good standing.
- Pharma tariffs not yet a headwind: Management stated the most recent U.S. tariff announcement does not impact generic players and may even benefit them; the situation is still evolving and Cipla has not been affected on any product.
- Executive order too recent to assess: With only one day since the orders were issued, management deferred any substantive read, noting generics are likely long-run beneficiaries and the orders are directed more at branded drugs than generic pricing.
Adukia: “we have not, in any way, got impacted by any -- and this is an evolving situation. We have to yet to see on what gets decided finally. But in our portfolio, we've not got impacted. And I think the most recent announcement doesn't really impact the generic players. In fact, it may just benefit.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | 23.5%–24.5% range | FY26 |
| U.S. quarterly revenue | ~$220 mn | Q1 FY26 |
| Peptide launches in U.S. | 3 assets (one large, two smaller); approvals expected in H2 | FY26 |
| Respiratory filings | 4 additional assets filed | Next 12–18 months |
| Peptide/complex generic filings | 10 additional assets filed | Next 12–24 months |
| Symbicort launch | Generic version launch | FY27 |
| Advair launch | Commercialized from U.S. site; launch depends on FDA priority | FY26 (early or late) |
| Inhaled insulin launch | India market | 3–4 months |
| Capex | ~5% of revenue | FY26 |
| R&D ceiling | Not to exceed 6–6.5% of revenue on a full-year basis | Ongoing |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹6,730 cr, +9% YoY |
| Full-year revenue | ₹27,548 cr, +8% YoY |
| EBITDA margin | 22.8%, +150 bps YoY |
| Full-year EBITDA margin | 25.9%, +139 bps YoY, exceeding guidance |
| Gross margin | 67.5%, +74 bps YoY |
| Full-year gross margin | 67.6%, +157 bps YoY |
| R&D spend | ₹426 cr, 6.3% of revenue |
| Full-year R&D spend | ₹1,524 cr, 5.5% of revenue |
| PAT | ₹1,222 cr, 18.2% of sales; effective tax rate 18.6% |
| Full-year PAT | ₹5,273 cr, 19.1% of sales; effective tax rate 22.4% |
| Net cash | ₹10,369 cr, after adjusting for debt of ₹438 cr including lease liabilities |
| FY26 EBITDA margin guidance | 23.5% to 24.5% |
| One India revenue growth | 8% YoY; full-year growth 7% YoY |
| One India chronic mix | 61.5% as per IQVIA MAT '25 |
| North America quarterly revenue | $221 mn; full-year revenue $934 mn |
| Albuterol market share | 18%, steady |
| One Africa revenue growth | 15% YoY in USD terms; full-year growth 12% YoY |
| One Africa private market secondary growth | 6.7% vs market growth of 4.9% |
| EMEU revenue growth | 16% YoY; full-year growth 15% YoY |
| U.S. Q1 FY26 revenue outlook | ~$220 mn |
| Respiratory share of global revenue | ~30% |
| Capex outlook | ~5% of revenue |
| India market growth rate range | 8% to 10%, down from 10% to 12% previously |
| South Africa normalized growth expectation | 4% to 5% |
| U.S. manufacturing split | ~1/3 from U.S., ~1/3 from India, ~1/3 from CMOs/rest of world |